文献速递前列腺癌

使用促黄体生成素释放激素激动剂或促性腺激素释放激素拮抗剂的前列腺癌患者的心血管风险

Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
PubMed 文献 · J Urol · 2023-10-05

基于美国真实世界数据回顾性分析45,059例接受雄激素剥夺治疗的前列腺癌男性,评估主要不良心血管事件(MACE)风险。结果显示,与LHRH激动剂相比,GnRH拮抗剂组的MACE风险更高(HR=1.62),全因死亡风险也更高(HR=1.87)。

要点

  • GnRH拮抗剂组MACE风险高于LHRH激动剂组(HR=1.62,95%CI 1.21-2.18,P=.001)。
  • GnRH拮抗剂组全因死亡风险高于LHRH激动剂组(HR=1.87,95%CI 1.39-2.51,P<.001)。
  • ADT启动后第一年MACE和全因死亡风险略低于后续年份。

核心结论

  • 调整后,接受GnRH拮抗剂治疗的前列腺癌男性MACE发生率高于接受LHRH激动剂者。
  • 对MACE风险影响最大的因素包括较高年龄、基线转移、肿瘤科(vs泌尿科)设置、个人MACE史、拮抗剂(vs激动剂)、吸烟史、白人(vs黑人)种族和较低BMI。

研究设计与样本

  • 回顾性分析Decision Resources Group(现Clarivate)真实世界证据数据库,覆盖1991至2020年美国所有地区超过3亿患者。
  • 纳入接受至少1次ADT注射的前列腺癌患者,共分析45,059例。
  • 以MACE和全因死亡为独立终点,构建Kaplan-Meier曲线,并使用SPSS通过Cox回归分析MACE与所有可用混杂危险因素的关联。

主要发现

  • GnRH拮抗剂组MACE风险高于LHRH激动剂组(HR=1.62;95%CI 1.21-2.18,P=.001)。
  • GnRH拮抗剂组全因死亡风险高于LHRH激动剂组(HR=1.87;95%CI 1.39-2.51,P<.001)。
  • ADT启动后第一年MACE和全因死亡风险略低于后续年份。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Luteinizing hormone-releasing hormone (LHRH) agonists are believed to have higher cardiovascular risk relative to gonadotropin-releasing hormone (GnRH) antagonists. However, previous studies have not consistently demonstrated this. We used real-world clinical practice data to evaluate differences in major adverse cardiovascular events (MACE) risk between LHRH agonists compared to a GnRH antagonist following androgen deprivation therapy (ADT) initiation. MATERIALS AND METHODS: We performed a retrospective analysis of data in the Decision Resources Group (now Clarivate) Real World Evidence repository, which represents >300 million US patients from 1991 to 2020 across all US regions. Patients with prostate cancer who received at least 1 injection of ADT were included. The risks of MACE and all-cause mortality as independent endpoints were evaluated, Kaplan-Meier curves were constructed, and associations between MACE and all available confounding risk factors were evaluated by Cox regression analysis using Statistical Package for the Social Sciences. RESULTS: A total of 45,059 men with prostate cancer treated with ADT were analyzed. Overall, the risks of MACE and all-cause mortality were slightly lower in the first year after ADT initiation compared to subsequent years. MACE risk was higher for the GnRH antagonist compared to LHRH agonists (HR=1.62; 95% CI 1.21-2.18, P = .001). The risk of all-cause mortality was also higher for the GnRH antagonist vs LHRH agonists (HR=1.87; 95% CI 1.39-2.51, P < .001). CONCLUSIONS: The adjusted incidence of MACE was higher for men treated with the GnRH antagonist compared to the LHRH agonists. The demographic and risk factors with the greatest impact on MACE risk were higher age, baseline metastasis, oncology (vs urology) setting, personal MACE history, antagonist (vs agonist), tobacco history, White (vs Black) race, and lower BMI.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Crawford ED, Hafron JM, Debruyne F, et al. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist. J Urol. 2023. PMID: 37796473. doi:10.1097/JU.0000000000003721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。